Bookmark

Add to MyYahoo RSS

Compugen News

News on Compugen (Ticker: CGEN) continually updated from thousands of sources around the net.

Thursday Jul 24 | Business Wire

Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences

Utilization of predictive discovery to identify 11 novel checkpoint molecules to be presented at Immunotherapies and Vaccines Summit in Boston Results for CGEN-15001 fusion protein based on checkpoint protein candidate to be presented at International Conference on Immune Tolerance in Amsterdam )--Compugen Ltd. today announced that it will present ... (more)

Comment?

Related Topix: Biotech, Healthcare Industry, Immunology, Biology, Science

Mon Jul 14, 2014

Business Wire

Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins

The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Oncology, Immunology, Biology, Science

Mon Jul 07, 2014

Business Wire

Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer

The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cancer, Health, Manufacturing, Bayer HealthCare, Chemicals, Oncology, Lung Cancer

Mon Jun 16, 2014

Freshnews

Compugen Discloses Experimental Results for Novel Checkpoint...

Compugen Ltd. disclosed today positive experimental results for CGEN-15052, a novel immune checkpoint candidate for cancer immunotherapy, which in several experimental settings demonstrated robust inhibition of T cell activation, both as a membrane protein and as an Fc fusion protein.

Comment?

Related Topix: Biotech, Healthcare Industry, Health, Lung Cancer, Immunology, Biology, Science

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••